Hedera Dx

📍 Epalinges, Switzerland🗓 Founded 2021👥 27 employees💰 Last funded May 2025
Biotechnology Research🌐 hederadx.com
Website LinkedIn
Liquid biopsies provide better therapy options for more patients. Hedera Dx is on a mission to provide the next billion people with access to modern cancer care. We specialize in clinic-ready, NGS-based liquid biopsies that enable non-invasive diagnosis, timely treatment selection, and longitudinal disease monitoring. Our culture is based on thinking different, modern and human, fostering a dynamic and innovative work environment. Join us on hederadx.com to learn more!
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2021
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Finland
2
Frequently asked questions
Who invested in Hedera Dx?
Hedera Dx has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Hedera Dx last raise funding?
The most recent investment in Hedera Dx recorded on gritt.io was in May 2025.
When was Hedera Dx founded?
Hedera Dx was founded in 2021.
What industry is Hedera Dx in?
Hedera Dx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Hedera Dx based?
Hedera Dx is headquartered in Epalinges, Switzerland.